Homosalate

Absorbs UVB radiation via the salicylate chromophore's π-conjugated system, converting UV photon energy to heat via internal conversion. Functions as a triplet energy acceptor for avobenzone, transferring excited-state energy away from avobenzone's photodegradation pathway, thereby functioning as a photostabiliser. The endocrine disruption mechanism is hypothesised to involve interaction with estrogen or androgen receptors, though the clinical significance of topical cosmetic exposure remains contested.

Up to 15% (FDA); up to 10% (EU); TGA recommends restriction to lower concentrations

Requires photostabiliser pairing. Stable in standard sunscreen oil phases. Often used in combination with avobenzone for full UVA/UVB coverage.

TGA April 2025 safety review concluded homosalate is not safe when used as a UV filter in cosmetic products at concentrations up to 10% based on SCCS assessment — potential endocrine disrupting activity. EU SCCS 2021 opinion: not safe above 1.4% in sunscreens due to endocrine disruption concern and systemic absorption above safety threshold. FDA GRASE non-determination pending. Detected in blood plasma and breast milk after topical application. Children: not recommended by paediatric toxicologists.

The TGA and SCCS safety concerns about homosalate represent genuine regulatory shift driven by endocrine disruption assessment — not clean-beauty hysteria. The ingredient's UV protection function is not disputed; the safety question at current formulated concentrations is unresolved pending regulatory finalisation.

Marketed as effective UVB filter and avobenzone stabiliser. Both accurate. The endocrine disruption concern is a legitimate regulatory finding, not solely a clean-beauty narrative.